ADMA Biologics Inc
Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported
"We're not buying more because of the volume going out the door, we're buying more because they're telling us to… I'm not seeing any trends that signal that it's really growing. I'm seeing more just moving stock and letting it sit on someone else's books… It's like cooking the books a bit."High-level employee at one of ADMA's two largest distributors — interviewed by Culper Research
ADMA's reported revenue growth is fabricated — driven entirely by a channel stuffing scheme, not by underlying end-market demand for ASCENIV.
Culper estimates that absent extended distributor payment terms and rebates, ADMA's revenues would have declined 3% in 2025 rather than the reported +20%. Distributor employees confirmed independently that ADMA induced them to carry 4–6 months of excess ASCENIV inventory by extending payment terms to 120 days and offering additional rebates, allowing ADMA to book revenues that were never supported by utilization. Third-party sales data reveals a gap between reported revenues and actual end-use of $14M (2023), $65M (2024), and $121M (2025), with an estimated $200M in cumulative channel inventory. Compounding the revenue manipulation, ADMA appears to distribute ASCENIV through Genesis BioPharma Services — a company sharing ADMA's corporate headquarters, apparently controlled by Vice Chairman Jerrold Grossman via Technomed Inc, yet never once disclosed in ADMA's related-party filings despite SEC rules requiring disclosure of transactions exceeding $120,000.
Fabricated Revenue Growth via Distributor Overloading
ADMA induced distributors to abandon monthly ordering cycles and carry 4–6 months of ASCENIV by extending payment terms to 120 days and offering rebates. Culper estimates this inflated 2025 revenues by $96M, producing the appearance of growth where underlying demand declined 3%.
Undisclosed Related-Party ASCENIV Distributor
Genesis BioPharma Services — which distributes ASCENIV, shares ADMA's corporate headquarters at 465 Route 17 South, Ramsey NJ, and is apparently controlled by Vice Chairman Grossman — has never appeared in ADMA's related-party disclosures, despite SEC rules requiring such disclosure.
DSO Surge Exposes Aggressive Revenue Recognition
Days sales outstanding skyrocketed from ~45 days pre-2025 to 113 days at year-end. ADMA reported $231M in Adj. EBITDA while generating just $50M in cash from operations — a divergence that widened every single quarter of 2025 and was never addressed by sell-side analysts.
$50M+ Insider Selling While Company Levers Up for Buybacks
ADMA borrowed $125M to repurchase stock while insiders collectively sold $50M+ over three years. CEO Grossman pledged 712,326 shares as personal loan collateral in January 2025 — coinciding precisely with the quarter receivables surged $49M and DSOs jumped from 43 to 78 days.
17-Year Auditor Resigned Independently; KPMG Flagged Critical Matters
CohnReznick resigned without seeking ADMA consent in October 2024. KPMG replaced them at more than 3× the prior fees, then flagged critical audit matters on Medicaid rebate accruals (2024 10-K) and inventory evidence sufficiency (2025 10-K). Director Bryant Fong resigned one month later; ADMA immediately vested his RSUs.
ASCENIV's Core Differentiation Is Becoming Obsolete
RSV vaccines approved in 2023 (Arexvy, Abrysvo, Nirsevimab) are making ASCENIV's high-titer advantage irrelevant as donor immunity converges. Competitor ALYGLO launched at roughly one-fourth the price and reached $106M in revenues. SCIG now accounts for 50% of PI patients, growing 2–3× faster than IVIG — and ADMA has no answer.
ASCENIV: Reported Revenue vs. Actual Utilization
Source: ADMA SEC filings; Culper Research proprietary third-party data provider · Annual 2023–2025 · USD millions
Days Sales Outstanding — Quarterly Escalation
Source: ADMA SEC filings, Culper Research analysis · Q4 2022 – Q4 2025 · Days
| Name / Entity | Role | Concern | Status |
|---|---|---|---|
| Adam Grossman | CEO | Sold $20.9M in ADMA stock over 3 years; entered 10b5-1 sale plans in December 2024 and November 2025; pledged 712,326 shares as collateral for a personal JPMorgan credit facility in January 2025; owns just 1.6% of the Company | Under Scrutiny |
| Jerrold Grossman | Vice Chairman & Founder | Appears to control Genesis BioPharma Services via Technomed Inc — an ASCENIV distributor operating from ADMA's corporate headquarters — never disclosed as a related party despite apparent material distribution relationship; sold $2.6M in stock in 2024–2025 | Under Scrutiny |
| CohnReznick LLP | Auditor (17 years) | Resigned independently on October 9, 2024, "without seeking or requiring consent from ADMA Biologics." Replaced by KPMG at more than 3× prior fees ($2.75M vs. $0.86M); KPMG flagged critical audit matters in both 2024 and 2025 10-K filings | Resigned |
| Bryant Fong | Director (resigned) | Resigned from the Board in November 2024, one month after the auditor's departure. ADMA agreed to immediately vest all 12,020 of his unvested RSUs in conjunction with his resignation | Departed |
| Brad Tade | CFO (retired) | "Retired" effective immediately on February 25, 2026 — the same day ADMA filed its 2025 10-K revealing 113-day DSOs. Notified ADMA just 5 days prior; approximately 52 years old at time of departure | Departed |
ADMA Biologics founded by father-son duo Jerrold and Adam Grossman. Completes a reverse merger with R&R Acquisition VI in 2012, then lists on NASDAQ in 2013.
FDA approves GSK's Arexvy and Pfizer's Abrysvo for adults (May); Sanofi/AZ's Nirsevimab for infants (July). By the 2024–2025 season, an estimated 66% of eligible infants receive RSV protection. ASCENIV's only claimed advantage — elevated RSV titers — begins losing relevance.
CohnReznick resigns without seeking or requiring ADMA's consent. KPMG is engaged as replacement at more than 3× the prior audit fee. KPMG subsequently flags a critical audit matter in both the 2024 and 2025 Form 10-K filings.
Long-tenured director Fong departs one month after the auditor's resignation. As part of the separation agreement, ADMA agrees to immediately vest all 12,020 of his unvested RSUs.
Adam Grossman pledges 712,326 shares — then worth approximately $12.8M at $17.97 per share — as collateral for a JPMorgan secured margin facility. The timing coincides with the onset of new payor coverage restrictions and the quarter in which ADMA's receivables surge $49M and DSOs jump from 43 to 78 days.
ADMA induces distributors to shift from monthly ordering to larger, more frequent purchases by offering rebates and extending payment terms to 120 days. Distributors accumulate 4–6 months of ASCENIV inventory. DSO climbs from 43 to 78, 84, 103, and ultimately 113 days by year-end 2025.
Grossman establishes a second automatic sale plan. In the Q3 2025 Form 10-Q, ADMA discloses a new risk factor referencing "our customers' inability to comply with the terms of our distribution agreements" — what Culper characterizes as a "CYA maneuver."
2025 10-K reveals DSO at 113 days and cash from operations of just $50M against $231M Adj. EBITDA. On the same day, CFO Brad Tade announces immediate retirement with just 5 days' prior notice, at approximately age 52.
ADMA announces a $125M accelerated share repurchase at $15.57 per share via JPMorgan, framing the transaction as reflecting "confidence in its long-term growth trajectory." Culper interprets it as an attempt to prop the share price ahead of continued insider selling.
Culper publishes its short thesis supported by distributor employee interviews, proprietary third-party ASCENIV sales data, ADMA's own financial disclosures, and state-level corporate filings.
Son of founder Jerrold Grossman. Entered 10b5-1 sale plans in December 2024 and November 2025. Estimated $20.9M in stock sales over three years. Pledged 712,326 shares as personal loan collateral in January 2025. Owns just 1.6% of the Company.
Father of CEO Adam Grossman. Appears to control Genesis BioPharma Services via Technomed Inc — an entity distributing ASCENIV from ADMA's own headquarters that has never been disclosed as a related party. Sold $2.6M in ADMA stock in 2024–2025. Owns 0.2% of the Company.
Self-described "life sciences logistics provider" explicitly listing ASCENIV among its products. Shares ADMA's corporate address at 465 Route 17 South, Ramsey, NJ. State corporate filings name Jerrold Grossman and his wife Marsha Goldman as officers of its parent, Technomed Inc. Never disclosed in ADMA's related-party filings.
Engaged after 17-year incumbent CohnReznick resigned independently. Charged more than 3× prior audit fees ($2.75M vs. $0.86M). Flagged critical audit matters on Medicaid rebate accruals (2024) and inventory audit evidence sufficiency (2025).
ADMA's ASCENIV revenues are inflated by 40% to 76% vs. what the Company's own disclosed patient count supports. CEO Grossman stated "over 1,000 patients or so" on ASCENIV in January 2026 — implying quarterly revenues of $59–75M against $104M actually reported for Q4 2025.Culper Research — March 24, 2026
The ASCENIV Growth Story Is Total Fiction
ADMA's reported revenue growth is fabricated, driven entirely by a de facto channel stuffing scheme in which distributor rebates and payment terms extended to 120 days generated $96M+ in 2025 revenues that were never supported by underlying demand. Third-party data confirms a widening, not narrowing, gap between reported revenues and actual utilization — with $200M in excess ASCENIV inventory now sitting in the channel. An apparently undisclosed related-party distributor controlled by Vice Chairman Grossman compounds the governance concern. With the auditor resigned, the CFO departed effective immediately, insiders having sold $50M+ over three years, and RSV vaccines systematically eroding ASCENIV's only claimed competitive advantage, Culper concludes that ADMA's $1.1 billion 2029 revenue target is total fantasy and shares are headed materially lower.
Primary Risk Factors$200M in channel inventory must be absorbed before distributors resume normal ordering. Revenue recognition will compress sharply once the stuffing cycle reverses, particularly given 6-month shelf-life constraints on specialty pharmacy acceptance.
UnitedHealthcare, Humana, and Aetna classify ASCENIV as non-preferred vs. 8–13 alternatives. CareFirst requires prior authorization from April 1, 2026. A former top-3 insurer decision-maker confirmed the real-world data strategy "doesn't really matter."
ALYGLO priced at roughly one-fourth ASCENIV's level is gaining momentum with heavy sales investment. Takeda's Gammagard Liquid ERC launched in January 2026. SCIG is growing at 2–3× IVIG with no ADMA response.
As RSV vaccines achieve ubiquitous uptake in donors, standard IVIG products will converge toward ASCENIV's titer profile — eliminating the product's sole claimed differentiation, which does not even extend to the FDA label.
Independent auditor resignation, two critical audit matters, simultaneous CFO departure at age 52, and an apparently undisclosed material related-party distribution relationship create acute SEC, restatement, and litigation exposure.
ADMA trades at 122.4× free cash flow and 7.2× revenues — multiples that embed consensus estimates anchored to $1.1B in 2029 ASCENIV revenues. Culper believes these estimates are built entirely on fictitious growth that will not recur.
This dashboard presents a summary of research published by Culper Research on March 24, 2026. All content, allegations, quotations, financial estimates, and conclusions contained herein are sourced exclusively from and attributed to Culper Research. Activ8 Insights has not independently verified any claims made in the underlying report and expresses no opinion as to their accuracy or completeness. This summary is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Use of Culper Research's research is at your own risk. You should assume that Culper Research and affiliated parties hold a position in ADMA Biologics Inc and may transact in these securities at any time. Culper's full disclaimer, terms of service, and restrictions on redistribution are available at http://www.culperresearch.com